# US 2016/0237413 A1 · Vulcanisaetal phosphotriesterase-like lactonases (pll) having enhanced properties and the uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0237413 A1
- Document ID: US20160237413A1
- Status: Published application
- Kind: A1
- Application number: 14/905,157
- Filed: 2014-07-31
- Published: 2016-08-18
- Earliest claimed: 2013-07-31
- Assignees: Centre National De La Recherche Scientifique; Universite D'Aix-Marseille
- Applicants: Centre National De La Recherche Scientifique; Universite D'Aix-Marseille
- Inventors: Eric CHABRIERE; Mikael ELIAS; Julien HIBLOT; Didier RAOULT
- Web page: https://patentgrep.com/patent/US20160237413A1

## CPC

- C12N 9/16: acting on ester bonds (3.1)
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A62D 3/02: by biological methods, i.e. processes using enzymes or microorganisms
- C11D 3/38636: {containing enzymes other than protease, amylase, lipase, cellulase, oxidase or reductase}
- C11D 3/48: Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
- C12N 9/18: Carboxylic ester hydrolases {(3.1.1)}
- A62D 2101/02: Chemical warfare substances, e.g. cholinesterase inhibitors
- A62D 2101/04: Pesticides, e.g. insecticides, herbicides, fungicides or nematocides
- A62D 2101/26: containing nitrogen or phosphorus
- C12Y 301/01: Carboxylic ester hydrolases (3.1.1)
- C12Y 301/08001: Aryldialkylphosphatase (3.1.8.1), i.e. paraoxonase
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A62D: CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
- C11D: DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C12Y: ENZYMES

## Abstract

Provided is a mutated hyperthermophilic PTE having a lactonase activity derived from a hyperthermophilic phosphotriesterase corresponding to the consensus sequence of SEQ ID NO: 1, the mutated PTE including the at least one mutation chosen amongst 55 putative positions and the mutated PTE having enhanced properties. Also provided are compositions including the mutated hyperthermophilic PTE and the uses thereof, notably as bioscavenger of organophosphate compounds or as quorum quencher of the bacteria using lactones to communicate.

## Claims

### Claim 1

A mutated hyperthermophilic phosphotriesterase (PTE) having a lactonase activity derived from a hyperthermophilic PTE corresponding to the sequence of SEQ ID NO: 1 or having at least 70% identity to the amino acid sequence of SEQ ID NO: 1,
said mutated PTE comprising at least one mutation selected from the group consisting of:
substitution of the valine L in position 29,
substitution of the tyrosine Y in position 99,
substitution of the tyrosine Y in position 101,
substitution of the arginine R in position 225,
substitution of the tryptophane W in position 265,
of SEQ ID NO: 1 by any other natural or non-natural amino acid.

### Claim 2 (depends on 1)

The mutated hyperthermophilic PTE having a lactonase activity according to claim 1, said mutated hyperthermophilic PTE being derived from a hyperthermophilic PTE of Vulcanisaeta moutnovskia corresponding to the sequence of SEQ ID NO: 3 or having at least 70% identity to the amino acid sequence of SEQ ID NO: 3,
said SEQ ID NO: 3 corresponding to SEQ ID NO: 1 in which the amino acid in position 2 is missing,
said mutated PTE comprising at least one mutation selected from the group consisting of:
substitution of the valine L in position 28,
substitution of the tyrosine Y in position 98,
substitution of the tyrosine Y in position 100,
substitution of the arginine R in position 224,
substitution of the tryptophane W in position 264,
of SEQ ID NO: 3 by any other natural or non-natural amino acid.

### Claim 3 (depends on 1)

The mutated hyperthermophilic PTE having a lactonase activity according to claim 1, said mutated PTE having at least 70% identity to the amino acid sequence SEQ ID NO: 3.

### Claim 4 (depends on 1)

The mutated hyperthermophilic PTE having a lactonase activity according to claim 1, wherein said mutated hyperthermophilic PTE having a lactonase activity possesses:
a greater phosphotriesterase activity, and/or
a greater lactonase activity, than that of the non-mutated hyperthermophilic PTE having a lactonase activity from which they derived.

### Claim 5 (depends on 2)

The mutated hyperthermophilic PTE having a lactonase activity according to claim 2, wherein the at least one mutation is selected from the group consisting of:
substitution of the leucine L in position 28 by a non-bulky amino acid selected from the group consisting of GPIADCSTN or by a hydrophobic amino acid selected from the group consisting of VIMFGAPWYC,
substitution of the tyrosine Y in position 98 by a bulky amino acid selected from the group consisting of EHKRQWFM or by a hydrophobic amino acid selected from the group consisting of VILMFGAPWC,
substitution of the tyrosine Y in position 100 by a bulky amino acid selected from the group consisting of EHKRQWFM or by a hydrophobic amino acid selected from the group consisting of VILMFGAPWC,
substitution of the arginine R in position 224 by a non-bulky amino acid selected from the group consisting of GPLIVADCSTN or by a polar amino acid selected from the group consisting of WYSTCQNKHDE,
substitution of the tryptophane W in position 264 by a hydrophobic amino acid selected from the group consisting of VILMFGAPYC or by a non-bulky amino acid selected from the group consisting of GPLIVACSTN.

### Claim 6 (depends on 2)

The mutated hyperthermophilic PTE having a lactonase activity according to claim 2, wherein the at least one mutation is selected from the group consisting of:
substitution of the leucine L in position 28 by an amino acid selected from the group consisting of AGV,
substitution of the tyrosine Y in position 100 by an amino acid E,
substitution of the arginine R in position 224 by an amino acid Q,
substitution of the tryptophane W in position 264 by an amino acid selected from the group consisting of ACGIMNPQRSTVYDEHKLF.

### Claim 7 (depends on 2)

The mutated hyperthermophilic PTE having a lactonase activity according to claim 2, wherein the at least one mutation is a single substitution of the leucine L in position 28 by an amino acid selected from the group consisting of ACGIMNPQRSTVYDEHKWF, in particular AGV.

### Claim 8 (depends on 2)

The mutated hyperthermophilic PTE having a lactonase activity according to claim 2, wherein the at least one mutation is a single substitution of the tyrosine Y in position 98 by an amino acid selected from the group consisting of ACGIMNPQRSTVWDEHKLF.

### Claim 9 (depends on 2)

The mutated hyperthermophilic PTE having a lactonase activity according to claim 2, wherein the at least one mutation is a single substitution of the tyrosine Y in position 100 by an amino acid selected from the group consisting of ACGIMNPQRSTVWDEHKLF, in particular E.

### Claim 10 (depends on 2)

The mutated hyperthermophilic PTE having a lactonase activity according to claim 2, wherein the at least one mutation is a single substitution of the arginine R in position 224 by an amino acid selected from the group consisting of ACGIMNPQWSTVYDEHKLF, in particular Q.

### Claim 11 (depends on 2)

The mutated hyperthermophilic PTE having a lactonase activity according to claim 2, wherein the at least one mutation is a single substitution of the tryptophane W in position 264 by an amino acid selected from the group consisting of ACGIMNPQRSTVYDEHKLF.

### Claim 12 (depends on 2)

The mutated hyperthermophilic PTE having a lactonase activity according to claim 2, said mutated hyperthermophilic PTE being chosen among the group consisting of the following sequences: SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 192, SEQ ID NO: 193, SEQ ID NO: 194, SEQ ID NO: 195, SEQ ID NO: 196, SEQ ID NO: 197, SEQ ID NO: 198, SEQ ID NO: 199, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 202, SEQ ID NO: 203, SEQ ID NO: 204, SEQ ID NO: 205, SEQ ID NO: 206, and SEQ ID NO: 207.

### Claim 13 (depends on 1)

A isolated nucleic acid sequence encoding the mutated hyperthermophilic PTE of claim 1.

### Claim 14 (depends on 13)

A vector comprising the nucleic acid as defined in claim 13.

### Claim 15 (depends on 14)

A host cell transformed by the vector as defined in claim 14.

### Claim 16 (depends on 1)

A composition comprising the mutated hyperthermophilic PTE of claim 1, in particular said composition further comprising at least:
one detergent or denaturing agent, or
one antibiotic selected from the group consisting of gentamycine, ciprofloxacin, ceftazidime, imipenem, tobramycine.

### Claim 17 (depends on 1)

A method for
decontamination of the surfaces of materials, of the skin, or mucous membranes, of hairs contaminated with organophosphorus compounds, or
prevention or treatment of an external or of an internal poisoning by ingestion or inhalation of organophosphorous compounds,
pollution control of water polluted with organophosphorus compounds, or
destruction of stocks of neurotoxic agents,
comprising applying an affective amount of a mutated hyperthermophilic PTE having a lactonase activity according to claim 1.

### Claim 18 (depends on 1)

Kit for the decontamination of the surfaces of materials, of skins or mucous membranes, of hairs, contaminated with organophosphorus compounds, or for the pollution control of water polluted with organophosphorus compounds, said kit comprising mutated hyperthermophilic PTE having a lactonase activity as defined in claim 1.

### Claim 19 (depends on 1)

Pharmaceutical composition comprising as active ingredient at least one mutated hyperthermophilic PTE having a lactonase activity as defined in claim 1 in combination with a pharmaceutically acceptable vehicle.

### Claim 20 (depends on 19)

Pharmaceutical composition as defined in claim 19 for use in the treatment of bacterial infections caused by bacteria using homoserin lactone substrates to communicate, in particular in the blood, wounds, burn, skin, biomaterial-body contact area, or for use in the treatment of eyes infection or eye surface healing.

### Claim 21 (depends on 1)

A method to disrupt quorum-sensing in bacteria,
in particular, to limit the formation of biofilms, notably in boats or other sea equipments,
in particular, to inhibit the fire blight in plants or to inhibit the rotting of vegetables,
comprising applying an effective amount of a mutated hyperthermophilic PTE as defined in claim 1.

### Claim 22 (depends on 1)

Phytosanitary composition comprising as active ingredient at least one mutated hyperthermophilic phosphotriesterase as defined in claim 1.

### Claim 23 (depends on 1)

Antibacterial composition comprising as active ingredient at least one mutated hyperthermophilic phosphotriesterase as defined in claim 1.
